Relationship between uric acid and bone mineral density in elderly type 2 diabetes

Abstract

Abstract: AIM: To study the relationship between uric acid (SUA) and bone mineral density　(BMD) in elderly type 2 diabetes.METHODS: The clinical data, SUA, and BMD (determined by dual energy x-ray absorptiometry [DXA]) of two hundred elderly type 2 diabetes patients were obtained. All the patients were divided into male group and female group; also they were further subdivided into hyperuricemia and normouricemia groups according to the level of SUA.The association between SUA and BMD from the respective groups were compared and analyzedRESULTS: SUA was positively related to BMD of lumbar spine (L_2-4) in elderly type 2 diabetes (r=0.236,P<0.05). BMD of males was significantly higher than that of females. SUA was an independent risk factor for BMD of L_2-4(β'=0.294,P<0.01). BMI and HDL-C were independent risk factors for BMD of t thigh bone.CONCLUSION: Maintaining certain blood uric acid level will be helpful to prevent osteoporosis in elderly type 2 diabetes.

Key words: uric acid, bone mineral density, elderly, type 2 diabetes

CLC Number:

RAUN Yuan, WU Tian-feng, YUAN Fang, WEN Xiao-lin. Relationship between uric acid and bone mineral density in elderly type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 567-570.

References

[1] Leidig-Bruckner G, Grobholz S, Bruckner T, et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus[J]. BMC Endocr Disord, 2014, 14: 1-13.
[2] Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease[J]. Cleve Clin J Med, 2008, 75(Suppl 5): S13-S16.
[3] 杨沿浪, 钟正灵, 汪裕伟, 等. 芜湖市健康体检人群慢性肾脏疾病患病率及相关危险因素调查[J]. 中国临床药理学与治疗学, 2014, 19(4): 430-436.
[4] Masseoud D, Rott K, Liu-Bryan R, et al. Overview of hyperuricaemia and gout[J]. Curr Pharm Des, 2005, 11(8): 4117-4124.
[5] Sugiura M, Nakamura M, Ogawa K, et al. Bone mineral density in post-menopausal female subjects is associated with serum antioxidant carotenoids[J]. Osteoporos Int, 2008, 19(2): 211-219.
[6] Sendur OF, Turan Y, Tastaban E, et al. Antioxidant status in patients with osteoporosis: a controlled study[J]. Joint Bone Spine, 2009, 76(5): 514-518.
[7] Ruiz-Ramos M, Vargas LA, Foaoul Van der Goes TI, et a1. Supplementation of ascorbic acid and alpha-toeopherol is useful to preventing bone loss linked to oxidative stress in elderly[J]. J Nutr Health Aging, 2010, 14(6): 467-472.
[8] Mackinnon ES, Rao AV, Ran LG. Dietary restriction of lycopene for a period of one month resulted in significantly increased biomarkers of oxidative stress and bone resorption in postmenopausal women [J]. J Nutr Health Aging, 2011, 15(2): 133-138.
[9] Nabipour I, Sambrook PN, Blyth FM, et al. Serum uric acid is associated with bone health in older men: A cross-sectional population-based study[J].J Bone Miner Res, 2011, 26(5): 955-964.
[10]Makoveya J, Macaraa M, Chen JS, et al. Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: A longitudinal study [J]. Bone, 2013, 52(1): 400-406.
[11]Lippi G, Montagnana M, Franchini M,et al. The paradoxical relationship between serum uric acid and cardiovascular disease [J]. Clin Chim Acta, 2008, 392(2): 1-7.
[12]Dytfeld J, Ignaszak-Szczepaniak M, Gowin E, et al. Influence of lean and fat mass on bone mineral density (BMD) in postmenopausal women with osteoporosis [J]. Arch Gerontol Geriatr 2011, 53(2): 237-242.
[13]林东平, 郭郁郁, 周筠,等. 中青年2型糖尿病患者血脂与骨密度关系[J]. 中国骨质疏松杂志, 2013, 19(6): 557-560.
[14]Hashemi M, Yavail M, Amiri N, et a1. Uric acid: a risk factor for coronary atherosclerosis [J]. Cardiovase J S Afr, 2007, 18(1): 16-19.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[4]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[5]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[6]	ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167.
[7]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[8]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[9]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[10]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[11]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[12]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[13]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[14]	LI Yongliang, LIN Haiyan, ZHANG Lingling, DONG Yilong. Effects of preoperative dezocine patient-controlled analgesia pump on stress response and cognitive function in elderly patients with lower extremity fractures [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 302-306.
[15]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.